Ontozry receives EC approval to treat drug-resistant focal-onset seizures in adults

1 April 2021

Privately-held Italy-based Angelini Group has announced that the European Commission (EC) has granted marketing authorization for Ontozry (cenobamate) for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adults who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products.

The EC marketing authorization is valid in all European Union (EU) member states plus Iceland, Norway and Liechtenstein. Ontozry is currently being reviewed via the reliance route by the UK’s Medicines and Healthcare Regulatory Agency (MHRA).

Pierluigi Antonelli, chief executive of Angelini Pharma, said: “Ontozry will be a welcome new treatment option in Europe for adults who have not yet been able to control their focal-onset seizures with available treatments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK